Skylark Bio is a biotechnology company that develops gene therapies to treat hearing losses.
Skylark Bio has raised $40.9M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in August 2022.
Skylark Bio is headquartered in Cambridge, United States.
Skylark Bio is a biotechnology company that develops gene therapies to treat hearing losses.
Skylark Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Skylark Bio — Funding & Investors." VCBacked, August 16, 2022, https://www.vcbacked.co/company/skylark-bio. Accessed August 14, 2026.
VCBacked. (2022). Skylark Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/skylark-bio
{{cite web |title=Skylark Bio — Funding & Investors |url=https://www.vcbacked.co/company/skylark-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated